Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Update on antiphospholipid syndrome.

Michael D Lockshin1

  • 1Barbara Volcker Center for Women and Rheumatic Disease, Mary Kirkland Center for Lupus Research, Joan and Sanford Weill Medical College of Cornell University, Hospital for Special Surgery, USA.

Bulletin of the NYU Hospital for Joint Diseases
|November 24, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria, Phase III-A/B Report: Defining and Structuring the Clinical and Laboratory Domains.

Current rheumatology reports·2025
Same author

Development of the 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria, Phase III-C Report: Assessment of Patient Scenarios (Derivation Cohort) and Refinement of Definitions.

Arthritis care & research·2025
Same author

Infant feeding experiences of women with systemic lupus erythematosus: A qualitative study.

Lupus·2025
Same author

Development of the 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria, Phase III-D Report: Multicriteria Decision Analysis.

Arthritis care & research·2024
Same author

The 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria.

Arthritis & rheumatology (Hoboken, N.J.)·2023
Same author

2023 ACR/EULAR antiphospholipid syndrome classification criteria.

Annals of the rheumatic diseases·2023
Same journal

Mosaicplasty for the treatment of the osteochondral lesion in the femoral head.

Bulletin of the NYU hospital for joint diseases·2012
Same journal

Hibernoma--a case series with multimodality imaging and pathologic correlation.

Bulletin of the NYU hospital for joint diseases·2012
Same journal

Progressive migration of broken Kirschner wire into the proximal tibia following tension-band wiring technique of a patellar fracture--case report.

Bulletin of the NYU hospital for joint diseases·2012
Same journal

Multidrug-resistant Acinetobacter baumannii infection following para-articular steroid injection in the knee--a case report.

Bulletin of the NYU hospital for joint diseases·2012
Same journal

Extensor indicis proprius and extensor digitorum communis rupture after volar locked plating of the distal radius--a case report.

Bulletin of the NYU hospital for joint diseases·2012
Same journal

Bilateral four-part anterior fracture dislocation of the shoulder--a case report and review of literature.

Bulletin of the NYU hospital for joint diseases·2012
See all related articles

The 2006 antiphospholipid syndrome criteria updated diagnostic timing and included new antibodies and clinical findings. Treatment for thrombosis remains warfarin, with ongoing investigation into treatment withdrawal.

Area of Science:

  • Rheumatology
  • Immunology
  • Hematology

Background:

  • The antiphospholipid syndrome (APS) is an autoimmune disorder associated with an increased risk of thrombosis and pregnancy morbidity.
  • Previous diagnostic criteria for APS were established in 1999.
  • Understanding of APS pathogenesis has evolved, implicating complement activation and innate immunity.

Purpose of the Study:

  • To summarize the revised diagnostic criteria for antiphospholipid syndrome published in 2006.
  • To highlight key changes from the previous 1999 criteria.
  • To discuss current understanding of APS pathogenesis and treatment.

Main Methods:

  • Review of the 2006 International Society on Thrombosis and Haemostasis APS diagnostic criteria.
  • Comparison of the 2006 criteria with the 1999 criteria.

Related Experiment Videos

  • Summary of updated information on APS pathogenesis and management.

    • Main Results:

    • Revised criteria increased the interval for laboratory confirmation from 6 to 12 weeks.
    • Antibody to beta2 glycoprotein I was accepted as a diagnostic criterion.
    • Associated findings like livedo reticularis, heart valve disease, and antibody to prothrombin were acknowledged; older age was excluded.
    • Pathogenesis concepts now include complement activation and innate immune system involvement.

    Conclusions:

    • The 2006 criteria refined APS diagnosis by adjusting laboratory requirements and incorporating new serological and clinical markers.
    • Current understanding emphasizes the role of complement and innate immunity in APS-related thrombosis.
    • Warfarin is the primary treatment for APS-related thrombosis, targeting an INR of 2.0-3.0, with potential for lifelong therapy; withdrawal strategies are under investigation.